AbCellera Biologics

ABCL

Market cap $1.17B

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026.

AbCellera Biologics Inc. (ABCL) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

AbCellera Biologics Inc. (ABCL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.11 per share a year ago.

AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Full Year 2025 Business Results.

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming Investor Conferences in March and April 2026.

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Full Year 2025 Financial Results on February 24, 2026.

AbCellera Biologics Inc. (ABCL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of VMS Due to Menopause.